DE60024415D1 - Die glycin-betain für seine antithrombotische verwendung - Google Patents

Die glycin-betain für seine antithrombotische verwendung

Info

Publication number
DE60024415D1
DE60024415D1 DE60024415T DE60024415T DE60024415D1 DE 60024415 D1 DE60024415 D1 DE 60024415D1 DE 60024415 T DE60024415 T DE 60024415T DE 60024415 T DE60024415 T DE 60024415T DE 60024415 D1 DE60024415 D1 DE 60024415D1
Authority
DE
Germany
Prior art keywords
betain
glycin
antithrombotic
antithrombotic use
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024415T
Other languages
English (en)
Other versions
DE60024415T2 (de
Inventor
Jallal Messadek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60024415D1 publication Critical patent/DE60024415D1/de
Publication of DE60024415T2 publication Critical patent/DE60024415T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60024415T 1999-03-02 2000-03-01 Glycin-betain zumr antithrombotischen gebrauch Expired - Lifetime DE60024415T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE9900144A BE1012495A3 (fr) 1999-03-02 1999-03-02 La glycine-betaine pour son usage antithrombotique.
BE9900144 1999-03-02
PCT/BE2000/000021 WO2000051596A1 (fr) 1999-03-02 2000-03-01 La glycine betaïne pour son usage antithrombotique

Publications (2)

Publication Number Publication Date
DE60024415D1 true DE60024415D1 (de) 2006-01-05
DE60024415T2 DE60024415T2 (de) 2006-09-21

Family

ID=3891794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024415T Expired - Lifetime DE60024415T2 (de) 1999-03-02 2000-03-01 Glycin-betain zumr antithrombotischen gebrauch

Country Status (20)

Country Link
US (1) US6855734B2 (de)
EP (1) EP1156796B1 (de)
JP (1) JP2002538113A (de)
KR (1) KR100767270B1 (de)
CN (1) CN1194681C (de)
AT (1) ATE311226T1 (de)
AU (1) AU2897900A (de)
BE (1) BE1012495A3 (de)
BR (1) BR0008631A (de)
CA (1) CA2362558C (de)
DE (1) DE60024415T2 (de)
EA (1) EA004047B1 (de)
ES (1) ES2254144T3 (de)
HK (1) HK1044276B (de)
HU (1) HUP0105397A3 (de)
IL (1) IL145068A0 (de)
MX (1) MXPA01008426A (de)
NZ (1) NZ513905A (de)
PL (1) PL204560B1 (de)
WO (1) WO2000051596A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900213A1 (hu) * 1999-02-01 2000-12-28 Gábor Bogye Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
WO2002062322A2 (en) * 2001-02-05 2002-08-15 Jallal Messadek Glycine betaine and its use as anti-hemorrhagic agent
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
NZ535323A (en) * 2002-02-25 2008-02-29 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US20060233877A1 (en) * 2002-11-25 2006-10-19 Jallal Messadek Betaine compositions
US8697679B2 (en) 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
ATE347358T1 (de) * 2003-04-17 2006-12-15 Jallal Messadek Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
WO2005011645A2 (en) * 2003-08-04 2005-02-10 Jallal Messadek Selected betaines and their uses
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
EP2242489A1 (de) 2005-02-15 2010-10-27 Jallal Messadek Zusammensetzungen für kombinationstherapie und anwendungsverfahren
EP1853544A4 (de) 2005-02-24 2010-06-16 Diffusion Pharmaceuticals Llc Trans-karotinoide, deren synthese, formulierung und verwendung
ATE540690T1 (de) 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
US9597311B2 (en) * 2005-09-27 2017-03-21 Robert Benson Aylor Suppression and prevention of tumors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
BRPI0810647A2 (pt) 2007-04-13 2014-11-04 Diffusion Pharmaceuticals Llc " uso de trans carotenóides bipolares como um pré-tratamento e no tratamento de doença vascular periférica ".
US8206751B2 (en) * 2007-10-31 2012-06-26 Diffusion Pharmaceuticals Llc Class of therapeutics that enhance small molecule diffusion
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
KR101875843B1 (ko) 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
EP2575487B1 (de) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Orale formulierungen aus bipolaren transkarotinoiden
CN115089569A (zh) 2016-03-24 2022-09-23 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途
CN109342606B (zh) * 2018-12-05 2021-11-02 宁波市产品食品质量检验研究院(宁波市纤维检验所) 一种水产品中甘氨酸甜菜碱的检测方法
US11285349B1 (en) * 2019-10-07 2022-03-29 TFS Holdings, LLC Sprinkler system antifreeze compositions and methods
CN111505131B (zh) * 2020-01-02 2023-03-31 东莞东华医院有限公司 基于血清代谢组学改变建立的预测冠心病斑块不稳定性临床模型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980277A (en) * 1987-10-16 1990-12-25 Cultor Ltd. Cryoprotectant solution and method
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
MC2041A1 (fr) * 1988-06-24 1990-05-30 Johannes Cornelius Str Andries Agents anti-atherogenic
AU1265295A (en) * 1993-12-10 1995-06-27 Sami A. Hashim Reducing likelihood of vascular disorders in susceptible patients
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
LV11727B (en) * 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
SE9601396D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6162852A (en) 1996-12-13 2000-12-19 Isolyser Company, Inc. Degradable polymers

Also Published As

Publication number Publication date
EP1156796A1 (de) 2001-11-28
ES2254144T3 (es) 2006-06-16
WO2000051596A1 (fr) 2000-09-08
EA200100925A1 (ru) 2002-04-25
DE60024415T2 (de) 2006-09-21
JP2002538113A (ja) 2002-11-12
ATE311226T1 (de) 2005-12-15
US6855734B2 (en) 2005-02-15
CA2362558A1 (fr) 2000-09-08
CN1342071A (zh) 2002-03-27
HUP0105397A3 (en) 2003-03-28
HUP0105397A2 (hu) 2002-05-29
HK1044276B (zh) 2006-12-22
PL204560B1 (pl) 2010-01-29
IL145068A0 (en) 2002-06-30
HK1044276A1 (en) 2002-10-18
WO2000051596A9 (fr) 2001-10-11
CN1194681C (zh) 2005-03-30
NZ513905A (en) 2001-09-28
EP1156796B1 (de) 2005-11-30
MXPA01008426A (es) 2003-06-06
CA2362558C (fr) 2009-06-02
BR0008631A (pt) 2002-02-13
EA004047B1 (ru) 2003-12-25
AU2897900A (en) 2000-09-21
KR20020021369A (ko) 2002-03-20
US20020065320A1 (en) 2002-05-30
PL350408A1 (en) 2002-12-02
KR100767270B1 (ko) 2007-10-17
BE1012495A3 (fr) 2000-11-07

Similar Documents

Publication Publication Date Title
DE60024415D1 (de) Die glycin-betain für seine antithrombotische verwendung
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
FI963101A0 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
CY1105020T1 (el) Υποκαταστατες διαζεπανες
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
ATE417856T1 (de) Motilidverbindungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATE330604T1 (de) Behandlung von manischen erkrankungen
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition